Research shows that cost-plus pricing can lower drug costs dramatically, depending on where in the supply chain the markup is applied.
|Articles|November 22, 2004
Risks of COX-2 vs. NSAID?
A 60-year-old Hispanic man, L.C., is being discharged from your hospital after an episode of gastrointestinal bleeding. Prior to admission he was switched to naproxen 500 mg b.i.d. for his osteoarthritis when rofecoxib (Vioxx, Merck) was taken off the market. Dismissal orders include ongoing medications: metformin 850 mg b.i.d., pravastatin 40 mg q.d., ramipril (Altace, Aventis) 10 mg q.d., now with the addition of lansoprazole (Prevacid, TAP) 30 mg q.d. L.C.'s physician is in a quandary about whether to prescribe a different COX-2 inhibitor or an NSAID. Previously, L.C. failed to obtain pain relief from acetaminophen or salsalate therapy. What do you recommend?
Advertisement
Advertisement
Related to this article
Medicaid and Part D low-income subsidy enrollment narrowed some gaps, but much of the disparity occurred within the same plans.
In part 1 of our midterm election FAQ series, AJ Barbarito, Esq, breaks down ongoing legal developments for pharmacists and what a change in Congressional control could mean for the profession.
A modeling study projects that a structured lifestyle program for adults with prediabetes would be cost-effective and likely cost saving.
As a government price-setting formula, the same arithmetic has produced the opposite result.
Orforglipron lowered A1C and body weight more than oral semaglutide 25 mg at 52 weeks, but the estimate comes from an indirect comparison.
Brian Smith, PharmD, explains how direct-to-consumer GLP-1 pathways broaden initial access but endanger long-term patient adherence.
Pharmacists face burnout and financial strain as PBMs take big cuts, prompting urgent calls for reform to protect patient care and community pharmacies.
Advertisement
Advertisement